Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 6/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7709135 | 0.90 | ADORA2A (0.58) | ADORA2A | |
| SCHEMBL7705941 | 0.88 | ADORA2A (0.51) | ADORA2A | |
| SCHEMBL7487423 | 0.86 | ADORA2A (0.56) | ADORA2A | |
| SCHEMBL7489489 | 0.86 | ADORA2A (0.58) | ADORA2A | |
| SCHEMBL7478262 | 0.86 | ADORA2A (0.56) | ADORA2A | |
| SCHEMBL7709129 | 0.85 | ADORA2A (0.56) | ADORA2A | |
| SCHEMBL7703244 | 0.85 | DPP4 (0.47) | ADORA2A | |
| SCHEMBL7708864 | 0.85 | TDO2 (0.41) | ADORA2A | |
| SCHEMBL7487041 | 0.85 | ADORA2A (0.51) | ADORA2A | |
| SCHEMBL7485299 | 0.84 | ADORA2A (0.56) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6355653-B1 | DRUG AND CARRIER FOR ANTIALLERGENS, BRAIN DISORDERS AND NEUROTRANSMITTERS | HOFFMANN-LA ROCHE INC. | 2002-03-12 | — | — | US | claimed |
| EP-1214322-A2 | AMINO-TRIAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-19 | — | — | EP | disclosed |
| US-6355653-B1 | DRUG AND CARRIER FOR ANTIALLERGENS, BRAIN DISORDERS AND NEUROTRANSMITTERS | HOFFMANN-LA ROCHE INC. | 2002-03-12 | — | — | US | disclosed |
| WO-2001017999-A2 | AMINO-TRIAZOLOPYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2001-03-15 | — | — | WO | disclosed |